NDA 208547 · Novartis
Netspot
Gallium Dotatate Ga-68 · Intravenous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Oct 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jun 1, 2016
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
65
7 Phase 3, 21 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Gallium Dotatate Ga-68" as an intervention, any sponsor and status, largest first.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00001277 · 1,553 participants · Start Dec 15, 1993 · Primary completion Mar 11, 2020
Drug: 68Ga-Dotatate; 18F-DOPA · For: Hyperparathyroidism; Hypercalcemia; Parathyroid Neoplasm and 2 more
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT04074135 · 740 participants (planned) · Start Jun 2, 2020 · Primary completion Jan 30, 2036
Drug: 68-Gallium DOTATATE · For: VHL Pancreatic Neuroendocrine Tumors; Von Hippel-Lindau Disease; Neuroendocrine Tumors
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT01967537 · 341 participants · Start Oct 18, 2013 · Primary completion Dec 17, 2017
Drug: 68Gallium DOTATATE · For: Neuroendocrine Tumors; Von Hippel-Lindau Syndrome; Hippel-Lindau Disease
Sites: Bethesda, Maryland
University of California, San FranciscoAcademic, hospital or other
NCT02177773 · 300 participants · Start Jun 23, 2014 · Primary completion Aug 7, 2017
Drug: Gallium Ga 68-Edotreotide · For: Neuroendocrine Tumor; Paraganglioma; Carcinoid Tumors and 1 more
Sites: San Francisco, California
Ochsner Health SystemAcademic, hospital or other
NCT02038738 · 250 participants (planned) · Start Mar 2014 · Primary completion Mar 2019
Drug: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. · For: Neuroendocrine; Neuroendocrine Tumor; Neuroendocrine Cancer and 5 more
Sites: Kenner, Louisiana
Sue O'DorisioAcademic, hospital or other
NCT01619865 · 223 participants · Start Feb 21, 2012 · Primary completion Aug 27, 2017
Drug: 68Ga-DOTATOC PET/CT · For: Neuroendocrine Tumors; Carcinoid Tumors; Neuroblastoma and 1 more
Sites: Iowa City, Iowa
Akiva MintzAcademic, hospital or other
NCT07284589 · 200 participants (planned) · Start Dec 11, 2025 · Primary completion Apr 30, 2030
Drug: 68Ga-Dotatate · For: Healthy (Controls); Healthy Volunteers; Neuroendocrine (NE) Tumors
Sites: Englewood, New Jersey
University Health Network, TorontoAcademic, hospital or other
NCT02743741 · 195 participants · Start Jul 15, 2016 · Primary completion Aug 18, 2026
Drug: Lutetium-177 Octreotate · For: Neuroendocrine Tumors
Sites: Hamilton, Canada; London, Canada; Toronto, Canada · 4 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.